In line with this, Douguet and coworkers showed that the activation of P2X7 can inhibit the growth of NSCLCs in mice receiving an anti-PD-1 therapy and therefore renders the tumor cells sensitive to this therapy [57]. Here, P2RX7 is linked to neoplasm.